Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Promising results for venetoclax across multiple hematological malignancies

Venetoclax is making headlines due to its effectiveness against many hematological cancers. In this video, Giovanni Martinelli, MD, of the Istituto Scientifico Romagnolo, Meldola, Italy, outlines how this drug is able to induce apoptosis in cancerous cells and how this has led to a recent breakthrough in drug development. Speaking at the 23rd Congress of the European Hematology Association (EHA) 2018, held at Stockholm, Sweden, Prof. Martinelli refers to his previous work that described the different metabolic pathways of cancerous and normal cells, and mentions how this is the starting point of action of venetoclax. Finally, Prof. Martinelli touches upon how the drug has been registered for treatment for chronic lymphocytic leukemia (CLL) due to its low patient toxicity, which leads to hopes for it to soon be applicable for other hematological malignancies.